Consolidated Balance Sheets - USD ($) $ in Millions		Dec. 31, 2023	Dec. 31, 2022
Assets
Cash and cash equivalents		$ 2,853	$ 416
Short-term investments		9,837	22,316
Trade accounts receivable, less allowance for doubtful accounts: 2023—$470; 2022—$449		11,177	10,952
Inventories	[1]	10,189	8,981
Current tax assets		3,978	3,577
Other current assets		5,299	5,017
Total current assets		43,333	51,259
Equity-method investments		11,637	11,033
Long-term investments		3,731	4,036
Property, plant and equipment		18,940	16,274
Identifiable intangible assets	[2]	64,900	43,370
Goodwill	[3]	67,783	51,375
Noncurrent deferred tax assets and other noncurrent tax assets		3,706	6,693
Other noncurrent assets		12,471	13,163
Total assets		226,501	197,205
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2023—$2,254; 2022—$2,560		10,350	2,945
Trade accounts payable		6,710	6,809
Dividends payable		2,372	2,303
Income taxes payable		2,349	1,587
Accrued compensation and related items		2,776	3,407
Deferred revenues		2,700	2,520
Other current liabilities		20,537	22,568
Total current liabilities		47,794	42,138
Long-term debt		61,538	32,884
Pension and postretirement benefit obligations		2,167	2,250
Noncurrent deferred tax liabilities		640	1,023
Other taxes payable		8,534	9,812
Other noncurrent liabilities		16,539	13,180
Total liabilities		137,213	101,288
Commitments and Contingencies
Preferred stock, no par value, at stated value; 27 shares authorized; no shares issued or outstanding as of December 31, 2023 and December 31, 2022		0	0
Common stock, $0.05 par value; 12,000 shares authorized; issued: 2023—9,562; 2022—9,519		478	476
Additional paid-in capital		92,631	91,802
Treasury stock, shares at cost: 2023—3,916; 2022—3,903		(114,487)	(113,969)
Retained earnings		118,353	125,656
Accumulated other comprehensive loss		(7,961)	(8,304)
Total Pfizer Inc. shareholders’ equity		89,014	95,661
Equity attributable to noncontrolling interests		274	256
Total equity		89,288	95,916
Total liabilities and equity		$ 226,501	$ 197,205

[1] The increase from December 31, 2022 of $1.2 billion reflects an increase of approximately $1.0 billion representing acquired Seagen inventory, inclusive of the fair value step-up (see Note 2A), and increases for certain products due to new product launches, supply recovery and changes in net market demand. These increases were offset to a large extent by $1.0 billion in inventory write-offs for Paxlovid and Comirnaty.

[2] The increase is primarily due to $28.8 billion for the acquisition of Seagen (see Note 2A) and the $495 million of capitalized milestones described in note (a) above, partially offset by amortization expense of $4.7 billion and impairments of $3.0 billion (see Note 4).

[3] Our goodwill balance continues to be assigned within the Biopharma reportable segment.